Equity research - Brisa

Mestrado em Finanças

Assistência na Doença aos Militares das Forças Armadas (ADM) – Que futuro?

Este trabalho tem por objetivo analisar a sustentabilidade da Assistência na Doença aos Militares (ADM), enquanto sistema autofinanciável. O autofinanciamento da ADM, com recurso exclusivo aos descontos efetuados pelos beneficiários, está, aparentemente em contradição com as disposições legais associadas à condição militar e isenta o Estado das suas obrigações. Esta é uma temática atual, cuja análise justifica um tratamento específico e singular, em consonância com as particularidades da condição militar, devendo, por isso, ser ponderados os diversos fatores condicionantes. Assim, partindo das despesas processadas pela ADM face às fontes de financiamento existentes, tentamos responder à questão central formulada - “Em que medida a ADM é sustentável e autofinanciável, com recurso exclusivo aos descontos dos beneficiários?”. Analisamos também se o regime optativo coloca em causa a sustentabilidade da ADM e em que medida esta decisão é condicionada pela perceção de que as disposições legais, relativas à condição militar, estão ou não a ser cumpridas. Concluímos que a ADM não é um sistema autofinanciável com recurso exclusivo aos descontos dos beneficiários, pelo menos por agora, pois suporta despesas que não são sua responsabilidade. Verificamos também que a maioria dos inquiridos, em caso de regime optativo, optaria por não descontar para a ADM, considerando o desconto elevado. Abstract: The Self-financing of the assistance in disease to Military (ADM) , with exclusive resource at the beneficiaries discounts , is disassociated from the military condition and relieves the State of its obligations. This is a current topic, whose analysis justifies specific and unique treatment in consonance with the characteristics of the military condition and should therefore be considered the various conditioning factors. This work aims to analyze the ADM sustainability, while a self-financing system. Thus, based on the expenses processed by ADM, as compared with existing funding sources, we try to answer the central question formulated - "To what extent ADM is sustainable and self-financing, with exclusive resource at the discounts of beneficiaries?". We also analysed if the optional regime puts into question the sustainability of ADM and to what extent this decision is conditioned by the perception that the legal provisions relating to the military condition, are being met or not. We conclude that ADM is not a self-financing system, with exclusive resource at the discounts of beneficiaries, at least for now and that supports expenses that are not their responsibility. We also verified that the majority of the inquired, would choose not discount for ADM, if optional regime is available, and considers the discount high.

Huambo Microbiology Laboratory : economical and financial viability

Mestrado em Finanças

Perpetual debt valuation: the net present value myopia

Would you prefer to receive a fixed rent for a period of 50 years, 75 years or perpetually? Well, if you have chosen the perpetual option, you are absolutely right. However, when considering a mathematical and financial approach, they may all end up roughly the same whenever the Net Present Value (NPV) is approximately identical. It makes common sense to choose the perpetual option even if the NPV exhibits myopia when computing the discount value of a fixed yearly rent. After a certain period, the discount value becomes approximately the same even when adding more yearly fixed rents. Corporations and governments issue perpetual bonds while recognizing these may not represent a very good financing strategy and thus implying that most of these issues are either callable or convertible on the issuer’s request. In approaching the existing perpetual debt related NPV myopia, this paper holds two main goals: firstly, we intend to study the behaviours of perpetual debt yields against other perpetual instruments and, secondly, we consider the financial methods for assessing the value of money before proposing a formula adjustment that might serve to overcome default NPV when evaluating fixed rents in perpetuity.

Determinants Of Firm Terminal Value: The Perspective Of North American And European Financial Analysts

Company valuation models attempt to estimate the value of a company in two stages: (1) comprising of a period of explicit analysis and (2) based on unlimited production period of cash flows obtained through a mathematical approach of perpetuity, which is the terminal value. In general, these models, whether they belong to the Dividend Discount Model (DDM), the Discount Cash Flow (DCF), or RIM (Residual Income Models) group, discount one attribute (dividends, free cash flow, or results) to a given discount rate. This discount rate, obtained in most cases by the CAPM (Capital asset pricing model) or APT (Arbitrage pricing theory) allows including in the analysis the cost of invested capital based on the risk taking of the attributes. However, one cannot ignore that the second stage of valuation that is usually 53-80% of the company value (Berkman et al., 1998) and is loaded with uncertainties. In this context, particular attention is needed to estimate the value of this portion of the company, under penalty of the assessment producing a high level of error. Mindful of this concern, this study sought to collect the perception of European and North American financial analysts on the key features of the company that they believe contribute most to its value. For this feat, we used a survey with closed answers. From the analysis of 123 valid responses using factor analysis, the authors conclude that there is great importance attached (1) to the life expectancy of the company, (2) to liquidity and operating performance, (3) to innovation and ability to allocate resources to R&D, and (4) to management capacity and capital structure, in determining the value of a company or business in long term. These results contribute to our belief that we can formulate a model for valuating companies and businesses where the results to be obtained in the evaluations are as close as possible to those found in the stock market

Perpetual debt valuation: the net present value myopia

Would you prefer to receive a fixed rent for a period of 50 years, 75 years or perpetually? Well, if you have chosen the perpetual option, you are absolutely right. However, when considering a mathematical and financial approach, they may all end up roughly the same whenever the Net Present Value (NPV) is approximately identical. It makes common sense to choose the perpetual option even if the NPV exhibits myopia when computing the discount value of a fixed yearly rent. After a certain period, the discount value becomes approximately the same even when adding more yearly fixed rents. Corporations and governments issue perpetual bonds while recognizing these may not represent a very good financing strategy and thus implying that most of these issues are either callable or convertible on the issuer’s request. In approaching the existing perpetual debt related NPV myopia, this paper holds two main goals: firstly, we intend to study the behaviours of perpetual debt yields against other perpetual instruments and, secondly, we consider the financial methods for assessing the value of money before proposing a formula adjustment that might serve to overcome default NPV when evaluating fixed rents in perpetuity.

Evaluación de costo efectividad de la profilaxis versus tratamiento a demanda en pacientes con Hemofilia A moderada y severa para prevenir sangrado articular de una aseguradora en Colombia

Introducción: En Colombia existe un protocolo de manejo para pacientes con hemofilia A severa sin inhibidores que recomienda el manejo de profilaxis primaria y secundaria con FVIII. Objetivos: Estimar la relación incremental de costo-efectividad (RICE) de la profilaxis con Factor VIII vs tratamiento a demanda para prevenir sangrados articulares en pacientes con hemofilia A moderada y severa de una aseguradora en Colombia. Materiales y Métodos: Se adaptó un modelo de Markov desde la perspectiva del tercer pagador. Las probabilidades de transición se ajustaron mediante un modelo de regresión logística multinomial explicadas por la edad y el peso. Las tasas de eventos son anuales. Las efectividades se extrajeron de la cohorte de la aseguradora y de la literatura. Los costos incluyeron el FVIII, medicamentos, hospitalización, procedimientos quirúrgicos, apoyo diagnóstico y consultas médicas. La tasa de descuento fue del 3%. Resultados: En pacientes con hemofilia A moderada y severa la profilaxis con FVIII evitará en promedio 7 sangrados articulares, el RICE para el sangrado articular es de $303.457. Conclusiones: La profilaxis con Factor VIII es una estrategia costo-efectiva en el manejo de pacientes con hemofilia A moderada y severa para la aseguradora, disminuyendo el número de sangrados articulares al año.